Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that the targeted therapy fruquintinib significantly improved overall survival (OS) and progression-free survival (PFS) in patients with refractory metastatic colorectal cancer.
A nonprofit does deals in Brazil and India to make low-cost CAR-T cell therapies widely available
In the latest bid to widen access to medicines, a nonprofit is sending technology and materials for making expensive CAR-T cell therapies to the Brazilian
May 8, 2024